Market Place
Sourcing Support
Panbela Provides Update & Reports Q3 2024 Financial Results
14 Nov 2024 //
GLOBENEWSWIRE
Panbela to Host Q3 2024 Earnings Call on Nov 14, 2024
31 Oct 2024 //
GLOBENEWSWIRE
First Patient Enrolled in STK11 Lung Cancer Phase I at Moffitt
24 Sep 2024 //
GLOBENEWSWIRE
Panbela Provides Business Update and Reports Q2 2024 Financial Results
13 Aug 2024 //
GLOBENEWSWIRE
Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024
30 Jul 2024 //
GLOBENEWSWIRE
Panbela`s Phase 3 ASPIRE Trial Gets DSMB Nod to Continue Without Changes
24 Jun 2024 //
GLOBENEWSWIRE
Panbela Announces Oral Presentation at Digestive Disease Week (DDW):
10 Jun 2024 //
GLOBENEWSWIRE
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
26 Mar 2024 //
GLOBENEWSWIRE
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference
12 Mar 2024 //
GLOBENEWSWIRE
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
29 Jan 2024 //
PRESS RELEASE
Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024
16 Jan 2024 //
GLOBENEWSWIRE
Panbela Announces Publication of Preclinical and Clinical Data Titled
02 Nov 2023 //
GLOBENEWSWIRE
Panbela and Moffitt partner to carry out trial of NSCLC therapy
23 May 2023 //
CLINICAL TRIALS ARENA
Panbela to Host First Quarter 2023 Earnings Conference Call on May 4, 2023
24 Apr 2023 //
GLOBENEWSWIRE
Panbela Announces Poster Presentation at American Association Cancer Research
19 Apr 2023 //
GLOBENEWSWIRE
Panbela Regains Worldwide Rights to Develop and Commercialize FlynpoviTM
11 Apr 2023 //
GLOBENEWSWIRE
Panbela Announces Agreement with Johns Hopkins University School of Medicine
03 Apr 2023 //
GLOBENEWSWIRE
Panbela Announces Issuance of New Patent in Japan
22 Mar 2023 //
GLOBENEWSWIRE
Panbela Provides Business Update and Reports Q4 and FY 2022 Financial Results
16 Mar 2023 //
GLOBENEWSWIRE
Panbela to Host Fourth Quarter and Year End 2022 Earnings Conference
08 Mar 2023 //
GLOBENEWSWIRE
Panbela Announces First Patient Enrolled in ASPIRE Trial Studying Ivospemin
07 Mar 2023 //
GLOBENEWSWIRE
Panbela Announces Closing of Approximately $15 Million Public Offering
13 Feb 2023 //
GLOBENEWSWIRE
Panbela Announces Pricing of Approximately $15 Million Public Offering
26 Jan 2023 //
GLOBENEWSWIRE
Panbela Announces 1-for-40 Reverse Stock Split effective January 13, 2023
12 Jan 2023 //
GLOBENEWSWIRE
Panbela Starts Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes
11 Jan 2023 //
GLOBENEWSWIRE
Panbela Receives EMA Opinion on Orphan Designation for Ivospemin
14 Dec 2022 //
GLOBENEWSWIRE
Panbela Announces First Patients Enrolled for ASPIRE Trial
28 Nov 2022 //
GLOBENEWSWIRE
Panbela Provides Business Update and Reports Q3 2022 Financial Results
10 Nov 2022 //
GLOBENEWSWIRE
Panbela Schedules Conference Call to Report 2022 Third Quarter Financial Results
31 Oct 2022 //
GLOBENEWSWIRE
Panbela to Participate in the Roth Inaugural Healthcare Opportunities Conference
06 Oct 2022 //
GLOBENEWSWIRE
Panbela Announces Pricing of Approximately $6 Million Public Offering
30 Sep 2022 //
GLOBENEWSWIRE
Panbela Receives Approvals to Open Sites in Spain, France & Italy for SBP-101
30 Sep 2022 //
GLOBENEWSWIRE
Panbela Provides Business Update and Reports Q2 2022 Financial Results
15 Aug 2022 //
GLOBENEWSWIRE
Panbela Announces First Patient Enrolled in its Aspire Trial Studying SBP-101
11 Aug 2022 //
GLOBENEWSWIRE
Panbela Expands Aspire Trial to Australia, Studying SBP-101 in Combination
04 Aug 2022 //
GLOBENEWSWIRE
Panbela to Report 2022 Second Quarter Financial Results
01 Aug 2022 //
GLOBENEWSWIRE
Panbela Announces Publication of Preclinical Data of SBP-101
28 Jun 2022 //
GLOBENEWSWIRE
Panbela Tx Closes Acquisition of Cancer Prevention Pharma
16 Jun 2022 //
GLOBENEWSWIRE
Panbela to Host Virtual R&D Day
27 Apr 2022 //
GLOBENEWSWIRE
Panbela Schedules Conference Call on May 12, 2022, to Report 2022
26 Apr 2022 //
GLOBENEWSWIRE
Panbela Announces Poster Presentation at AACR
12 Apr 2022 //
GLOBENEWSWIRE
Panbela Provides Business Update and Reports Q4 and FY 2021 Financial Results
24 Mar 2022 //
GLOBENEWSWIRE
Panbela to Participate in a Panel Discussion
23 Mar 2022 //
GLOBENEWSWIRE
Panbela to Participate in the 34th Annual Roth Conference
10 Mar 2022 //
GLOBENEWSWIRE
Panbela to Report 2021 Q4 Financial Results
08 Mar 2022 //
GLOBENEWSWIRE
Panbela Therapeutics, Inc. to Acquire Cancer Prevention Pharmaceuticals, Inc.
22 Feb 2022 //
GLOBENEWSWIRE
Panbela Therapeutics, Inc. to Acquire Cancer Prevention Pharmaceuticals, Inc.
22 Feb 2022 //
BIOSPACE
Panbela Initiates ASPIRE Study of SBP-101 with Nab-Paclitaxel & Gemcitabine
26 Jan 2022 //
GLOBENEWSWIRE
Panbela Presents Clinical Data on Phase 1b Trial of SBP-101 in Metastatic PDA
24 Jan 2022 //
GLOBENEWSWIRE
Panbela Announces Positive Preclinical Strongly Supporting Activity of SBP-101
14 Dec 2021 //
GLOBENEWSWIRE
Panbela Announces Acceptance of Abstract for Poster Presentation at ASCO
18 Nov 2021 //
GLOBENEWSWIRE
Panbela Call on August 11, 2021, to Report 2021 2nd Quarter Financial Result
28 Jul 2021 //
GLOBENEWSWIRE
Panbela to Present at Access to Giving Virtual Conference on July 15, 2021
07 Jul 2021 //
GLOBENEWSWIRE
PANBELA ANNOUNCES CLOSING OF $10.0M BOUGHT DEAL OFFERING OF COMMON STOCK
02 Jul 2021 //
GLOBENEWSWIRE
Panbela Increases Previously Announced Bought Deal Offering Of Common Stock
29 Jun 2021 //
GLOBENEWSWIRE
PANBELA THERAPEUTICS ANNOUNCES $5.0 MILLION BOUGHT DEAL OFFERING OF COMMON STOCK
29 Jun 2021 //
GLOBENEWSWIRE
Panbela Announces Partial Clinical Hold Lifted on Phase I Polyamine Metabolic
16 Apr 2021 //
GLOBENEWSWIRE
Panbela Announces Acceptance of Abstract for Poster Presentation
06 Apr 2021 //
GLOBENEWSWIRE
Panbela Announces Research Agreement with Johns Hopkins University
10 Feb 2021 //
GLOBENEWSWIRE
